Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17868781 | 0.86 | KMT2A (0.46) | MEN1KMT2AALDH1A1POLBKDM4E | |
| SCHEMBL7893820 | 0.83 | KMT2A (0.67) | MEN1KMT2AALDH1A1CA2POLB | |
| SCHEMBL9781400 | 0.79 | MEN1 (0.70) | MEN1KMT2AALDH1A1CA2POLB | |
| SCHEMBL9119369 | 0.79 | KMT2A (0.70) | MEN1KMT2AALDH1A1CA2POLB | |
| SCHEMBL9119354 | 0.79 | KMT2A (0.70) | MEN1KMT2AALDH1A1CA2POLB | |
| SCHEMBL9781310 | 0.77 | MEN1 (0.68) | MEN1KMT2AALDH1A1CA2POLB | |
| SCHEMBL4689993 | 0.77 | MEN1 (0.68) | MEN1KMT2AALDH1A1CA2POLB | |
| SCHEMBL12472188 | 0.76 | CASR (0.55) | MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL11673049 | 0.76 | ALDH1A1 (0.62) | MEN1KMT2AALDH1A1CA2POLB | |
| SCHEMBL9781396 | 0.76 | MEN1 (0.58) | MEN1KMT2AALDH1A1CA2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9902710-B2 | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) | EXONHIT THERAPEUTICS, SA (FR) | 2018-02-27 | — | — | US | disclosed |
| US-9902710-B2 | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) | EXONHIT THERAPEUTICS, SA (FR) | 2018-02-27 | — | — | US | disclosed |
| US-9902710-B2 | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) | EXONHIT THERAPEUTICS, SA (FR) | 2018-02-27 | — | — | US | disclosed |
| US-20160264549-A1 | SUBSTITUTED 6, 7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A) | EXONHIT THERAPEUTICS, SA (FR) | 2016-09-15 | — | — | US | disclosed |
| US-20160264549-A1 | SUBSTITUTED 6, 7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A) | EXONHIT THERAPEUTICS, SA (FR) | 2016-09-15 | — | — | US | disclosed |
| US-20160264549-A1 | SUBSTITUTED 6, 7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A) | EXONHIT THERAPEUTICS, SA (FR) | 2016-09-15 | — | — | US | disclosed |
| US-9200016-B2 | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) | ALLERGAN, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9200016-B2 | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) | ALLERGAN, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9200016-B2 | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) | ALLERGAN, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150158895-A1 | SUBSTITUTED 6, 7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A) | ALLERGAN, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-20150158895-A1 | SUBSTITUTED 6, 7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A) | ALLERGAN, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-20150158895-A1 | SUBSTITUTED 6, 7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A) | ALLERGAN, INC. (US) | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264549-A1 | SUBSTITUTED 6, 7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A) | PDE9A, PDE10A, PDE6A | MEN1 4048/4885KMT2A 2096/4885ALDH1A1 186/4885 |
| US-20150158895-A1 | SUBSTITUTED 6, 7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A) | PDE9A, PDE10A, PDE6A | MEN1 4048/4885KMT2A 2096/4885ALDH1A1 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.